Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
Cancer is one of the deadliest diseases, causing million of deaths each year globally. Conventional anti-cancer therapies are non-targeted and have systemic toxicities limiting their versatile applications in many cancers. So, there is an unmet need for more specific therapeutic options that will be...
Main Authors: | Devesh Aggarwal, Jie Yang, Md. Abdus Salam, Sagnik Sengupta, Md. Yusuf Al-Amin, Saad Mustafa, Mohammad Aasif Khan, Xun Huang, Jogendra Singh Pawar |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1203073/full |
Similar Items
-
Antibody–Drug Conjugates: The Last Decade
by: Nicolas Joubert, et al.
Published: (2020-09-01) -
Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01) -
Antibody–Drug Conjugates for Cancer Therapy
by: Umbreen Hafeez, et al.
Published: (2020-10-01) -
Business Risk Mitigation in the Development Process of New Monoclonal Antibody Drug Conjugates for Cancer Treatment
by: Balázs Kiss, et al.
Published: (2023-06-01) -
Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma
by: Ali Al Sbihi, et al.
Published: (2024-02-01)